BES Group and Associates Solutions Plus - Houston Texas

BES Group and Associates Solutions Plus - Houston, TX

Bes Group And Associates Solutions Plus is treatment center located at 4625 North Freeway, Suite 127 in the 77022 zip code in Houston, TX that offers medication assisted substance abuse treatment. Bes Group And Associates Solutions Plus provides suboxone prescription, relapse prevention from naltrexone and naltrexone administration to children and adolescents. Some of the treatment approaches used by Bes Group And Associates Solutions Plus consist of cognitive behavioral therapy, motivational interviewing and anger management. Bes Group And Associates Solutions Plus also offers detox services and offers opioid detox, methamphetamines detoxification and cocaine detoxification.

Address: 4625 North Freeway, Suite 127, Houston, TX 77022

1. Types of Care
2. Service Settings
3. Opioid Medications used in Treatment
4. Type of Alcohol Use Disorder Treatment
5. Type Of Treatment
6. Pharmacotherapies
7. Treatment Approaches
8. FacilityOwnership
9. License/Certification/Accreditation
10. Payment/Insurance/Funding Accepted
11. Assessment/Pre-treatment
12. Screening & Testing
13. Transitional Services
14. Ancillary Services
15. Detoxification
16. Counseling Services and Education
17. Tobacco/Screening Services
18. Facility Smoking Policy
19. Age Groups Accepted
20. Gender Accepted
21. Exclusive Services

Here are the full facility listing details on BES Group and Associates Solutions Plus in Houston, TX:

Phone #: 832-389-2982

Is Methadone a safe option for addiction treatment?

Methadone treatment can be a safe and effective option for individuals struggling with opioid addiction, especially when administered under the supervision of a qualified healthcare provider as part of a comprehensive addiction treatment program, such as the one that can be found at BES Group and Associates Solutions Plus. Methadone is an opioid medication that is used to help manage opioid withdrawal symptoms and cravings, making it easier for individuals to reduce or quit their use of other opioids like heroin or prescription painkillers.

Here are some key points to consider regarding the safety of methadone treatment:

1. Supervised Administration: Methadone treatment is typically provided through opioid treatment programs (OTPs) or clinics where patients receive a daily dose of methadone under the supervision of healthcare professionals. This helps reduce the risk of misuse and overdose.

2. Reduces Withdrawal Symptoms: Methadone can alleviate the severe withdrawal symptoms associated with opioids, which can be a significant barrier to recovery. This can enhance the patient's quality of life and make it easier for them to engage in therapy and counseling.

3. Harm Reduction: Methadone maintenance treatment can be viewed as a harm reduction approach. While it doesn't necessarily lead to immediate abstinence, it reduces the risks associated with illicit opioid use, such as overdose and the transmission of infectious diseases (e.g., HIV and hepatitis).

4. Individualized Treatment: Methadone treatment should be individualized to meet the unique needs of each patient. The dose is typically adjusted based on the patient's response and progress in treatment.

5. Legal Regulation: Methadone clinics and providers are subject to strict regulations and oversight by government agencies to ensure safety and appropriate use of the medication.

However, it's important to note that methadone is an opioid itself and can be habit-forming. When taken as prescribed and under medical supervision, the risk of addiction to methadone is relatively low. However, misuse or diversion of methadone can lead to addiction and other negative consequences.

Methadone treatment is not suitable for everyone. Individuals with certain medical conditions or contraindications may not be candidates for methadone treatment. It's essential for addiction treatment centers like BES Group and Associates Solutions Plus to conduct a thorough assessment before starting someone on methadone.